Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

China’s National Medical Products Administration has given the thumbs up to Akeso Pharmaceuticals Inc.’s ebdarokimab for treating moderate to severe plaque psoriasis in adults. An interleukin ...

Roche AG has become the latest pharmaceutical company to respond to the Trump administration’s threat to impose tariffs, saying it will invest $50 billion in drug and diagnostics manufacturing in the ...

Art Garfunkel discusses his experience living with psoriasis as part of Sun Pharma’s I LUV YA for The Long Haul campaign.

GLP-1s exploded seemingly out of nowhere, straining pharmacy plan bottom lines. Psoriasis treatments don't have to follow the ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

Learn more about whether Alvotech or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

Discover the signs of psoriatic arthritis, from joint pain and skin changes to nail damage and fatigue, plus the latest treatment options for this condition.

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...